UK begins trials of Ebola vaccine developed in just eight weeks

• UK medicines regulator has approved clinical trials of a novel Ebola vaccine developed in eight weeks, demonstrating rapid vaccine development capability in response to emerging threats
• The vaccine will be tested on healthy adult volunteers, establishing safety and immunogenicity data in the UK population
• This accelerated development timeline highlights potential for faster regulatory pathways in responding to future infectious disease outbreaks

The UK medicines regulator has given approval for an experimental vaccine to be tested on healthy adults.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.